फ्लुवोक्सामिन और रैमेल्टियॉन का इंटरैक्शन

Ramelteon: Should not be used in combination with fluvoxamine ( 5.8 ).

Ramelteon should not be used in combination with fluvoxamine.

Ramelteon: When fluvoxamine 100 mg twice daily was administered for 3 days prior to single-dose coadministration of ramelteon 16 mg and fluvoxamine, the AUC for ramelteon increased approximately 190-fold and the C max increased approximately 70-fold compared to ramelteon administered alone.

Ramelteon: See Warnings and Precautions ( 5.8 ) .

Patients should not take ROZEREM in conjunction with fluvoxamine [see Drug Interactions (7) ] .

ROZEREM should not be used in combination with fluvoxamine [see Contraindications (4) , Clinical Pharmacology (12.5) ] .

Fluvoxamine (strong CYP1A2 inhibitor): Increases AUC for ramelteon and should not be used in combination.

Effects of Other Drugs on ROZEREM Fluvoxamine (strong CYP1A2 inhibitor) AUC 0-inf for ramelteon increased approximately 190-fold, and the C max increased approximately 70-fold upon coadministration of fluvoxamine and ROZEREM, compared to ROZEREM administered alone.

ROZEREM should be administered with caution to patients taking less strong CYP1A2 inhibitors.